Published online Aug 27, 2024. doi: 10.4240/wjgs.v16.i8.2374
Revised: May 5, 2024
Accepted: June 3, 2024
Published online: August 27, 2024
Processing time: 159 Days and 1.7 Hours
In this editorial, we comment on the article “Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis” by Liu et al that was published in the recent issue of the World Journal of Gastroin
Core Tip: Immunotherapy is an important treatment method for solid tumors nowadays. However, liver metastasis leads to a decrease in the efficacy of immunotherapy for malignant tumors. The main reason is that liver metastasis can promote the depletion of systemic CD8(+) T cells by utilizing the host's peripheral immune tolerance mechanism, thereby leading to a systemic immune tolerance environment. In the dilemma of limited efficacy of immunotherapy alone, the combination with chemotherapy, radiotherapy, targeted therapy, and other anti-tumor methods can significantly enhance the efficacy of immunotherapy, holding important clinical prospects.
- Citation: Jiang C, Zhang ZH, Li JX. Consideration on immunotherapy of liver metastases of malignant tumors. World J Gastrointest Surg 2024; 16(8): 2374-2381
- URL: https://www.wjgnet.com/1948-9366/full/v16/i8/2374.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v16.i8.2374
Metastases often occur in the advanced stage of malignant tumors. Although different tumors often have different tendencies towards the metastatic organs, the liver is the organ most susceptible to metastasis due to its unique anatomical position, cell metabolism, and immune microenvironment[1]. Liver metastasis substantially impacts patient survival. Studies have shown that patients with liver metastasis have a poorer prognosis compared to those with other organ metastases[2]. There are different pathological types of liver metastasis, with the most common pathologic type reported being not otherwise specified (NOS) adenocarcinoma (74.9%). Most NOS adenocarcinomas originate from the digestive tract (68.2%), especially from the colorectum (46.1%)[3]. There are three different histopathological growth patterns (HGPs) of metastatic cancer cells, including: (1) Desmoplastic type; (2) Replacement type; and (3) Pushing type[4]. Different HGP subtypes have different cytokine profiles and varying levels of lymphocyte infiltration[5]. The HGP of liver metastasis in different tumors is also different. For example, the most common manifestation of liver metastasis in uveal melanoma and breast cancer is replacement type[6,7]; in liver metastases of digestive tract tumors such as gastrointestinal and pancreatic malignancies, the occurrence frequency of the three HGP subtypes is approximately equal[8]. Multiple studies have shown that the prognosis of different HGP subtypes of liver metastasis varies, with patients with desmoplastic HGP having the best prognosis[7,9]. However, some studies have found that patients with non-desmoplastic HGP are more likely to benefit from adjuvant chemotherapy[10]. If HGP can be included in the treatment decisions for liver metastasis patients, it may benefit patients and thus improve their prognosis.
Despite distant metastasis indicating the advanced stage of malignant tumors, in recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has become a major breakthrough in the field of malignant tumor treatment, changing the treatment decisions for various solid tumors[11]. For the overall population, immunotherapy provides survival benefits for patients with liver metastasis, but it has been observed in various malignant tumors that the benefits of immunotherapy are significantly reduced compared to patients without liver metastasis. For example, Botticelli et al[12] found that the metastasis of urothelial carcinoma to lymph nodes was completely relieved by ICIs treatment, while the metastasis to the liver showed resistance to such treatment. Takeyasu et al's[13] study on non-small cell lung cancer (NSCLC) found that liver metastasis was associated with poorer median progression-free survival (PFS) after treatment with pembrolizumab (3.4 mo vs 9.4 mo, P = 0.0018). Similar findings were reported by Tumeh et al[14], who found that pembrolizumab immunotherapy for melanoma also showed poorer immunotherapy outcomes in patients with liver metastases. A multicenter clinical study on stage IV melanoma showed that the liver metastasis group had poorer response to anti PD-1 monoclonal antibody therapy compared to the non-liver metastasis group, with a significantly lower objective response rate (ORR; 4.3% vs 20.7%, P < 0.05)[15]. In the recent issue of the World Journal of Gastroenterology Surgery, Liu et al[16] published an interesting paper revealing that in patients with advanced gastric cancer who received immunotherapy, PFS was significantly worse in the liver metastasis group compared to the non-liver metastasis group (5.0 mo vs 11.2 mo, P < 0.05). The reason for this clinical phenomenon is currently believed to be liver metastasis leading to immune tolerance.
Liver immune tolerance is a recognized concept[17,18], and it is currently believed that the liver is a key frontline immune organ, with its default immune state mainly being anti-inflammatory or immune tolerance. Under appropriate conditions, the liver is capable of mounting rapid and robust immune responses as well. The balance between immunity and tolerance is crucial for liver function[19]. Peripheral T cells are key participants in adaptive immune responses, and multiple mechanisms lead to depletion or inhibition of peripheral T cells in the liver, resulting in immune tolerance. Preclinical studies have found that metastatic liver cancer can induce systemic tumor-specific CD8(+) T cell loss through the Fas-FasL pathway, leading to reduced efficacy of immunotherapy[20]. Comprehensive sequencing of primary tumors (including melanoma, NSCLC, etc.) from patients with metastatic cancer showed a decrease in T cell clonality and diversity, and a decrease in T cell effector capacity in patients with liver metastasis[21]. Tumeh et al's[14] study on biopsy specimens of melanoma liver metastasis found that compared to the non-liver metastasis group, the CD8(+) T cell count at the infiltrating edge of the liver metastasis group was significantly reduced (547 vs 1441, P <0.05). Analysis of the distribution of primary tumor and liver metastatic tumor cells in patients with liver metastasis of colorectal cancer by He et al[22], revealed that there were more immunosuppressive cells in liver metastases, among which the distribution difference of macrophages was the most obvious. This may be related to intrahepatic immunosuppression and poor immunotherapy efficacy. The lymph nodes, skin, and lungs are areas where anti-tumor immunity is easily beneficial, which may be attributed to the presence of a large number of immune cells in these specific organs[23].
Reversing the immunosuppressive state and improving the efficacy of immunotherapy in patients with liver metastasis are the key to treating liver metastasis. At present, the main approach is to combine another treatment method to improve the efficacy of immunotherapy. However, clinical research on the immunotherapy-based combination therapy for liver metastasis of malignant tumors is limited, with more focus on preclinical studies or case reports (Table 1).
Cancer | Ref. | Type | Combination | Treatment strategy |
Lung cancer | Ma et al[45] | Clinical study | Immunotherapy + targeted therapy | Anti-PD-1 + anlotinib |
Jiang et al[46] | Preclinical study | Immunotherapy + targeted therapy + radiotherapy | Anti-PD-1 + anlotinib + radiotherapy | |
Gadgeel et al[24] | Clinical study | Immunotherapy + chemotherapy | Pembrolizumab + pemetrexed | |
Socinski et al[34] | Clinical study | Immunotherapy + targeted therapy + chemotherapy | Atezolizumab + bevacizumab + carboplatin + paclitaxel | |
Hellmann et al[35] | Clinical study | Dual immunotherapy | Nivolumab + ipilimumab | |
Colorectal cancer | Ragusa et al[33] | Preclinical study | Immunotherapy + targeted therapy | Anti-PD-1 + VEGF inhibitors |
Song et al[39] | Preclinical study | Immunotherapy + targeted therapy | Anti-PD-L1 + lipopolysaccharide block | |
Wang et al[47] | Clinical study | Immunotherapy + targeted therapy | Toripalimab + regorafenib | |
Eng et al[48] | Clinical study | Immunotherapy + targeted therapy | Atezolizumab + cobimetinib | |
Hu et al[40] | Preclinical study | Immunotherapy + gene therapy | Anti-PD-1 + relaxin gene therapy | |
Kadota et al[49] | Preclinical study | Immunotherapy + targeted therapy | Anti-PD-1 + dasatinib | |
Inoue et al[26] | Clinical study | Immunotherapy + chemotherapy | Cetuximab + chemotherapy | |
Pancreatic cancer | Ho et al[29] | Preclinical study | Immunotherapy + chemotherapy | Anti-PD-1 + gemcitabine |
Qiu et al[50] | Clinical study | Immunotherapy + targeted therapy | Sintilimab + anlotinib + S-1 | |
Blair et al[51] | Preclinical study | Immunotherapy + targeted therapy | Anti-PD-1 + focal adhesion kinase inhibitor (FAKi) + Anti-CXCR4 antibody | |
Matsumoto et al[38] | Preclinical study | Immunotherapy + targeted therapy | Alpha-galactosylceramide (KRN7000) + angiogenesis inhibitor AGM-1470 (TNP470) | |
Hu et al[40] | Preclinical study | Immunotherapy + gene therapy | Anti-PD-1 + relaxin gene therapy | |
Zhang et al[52] | Case report | Immunotherapy + chemotherapy | Penpulimab + modified FOLFIRINOX | |
Breast cancer | Schmid et al[53] | Clinical study | Immunotherapy + chemotherapy | Atezolizumab + nab-paclitaxel |
Yu et al[20] | Preclinical study | Immunotherapy + radiotherapy | Anti-PD-L1 + radiotherapy | |
Lee et al[21] | Preclinical study | Immunotherapy + targeted therapy | Anti-PD-1 + regulatory T cells targeting therapy | |
Hu et al[40] | Preclinical study | Immunotherapy + gene therapy | Anti-PD-1 + relaxin gene therapy | |
Ozaki et al[54] | Clinical study | Immunotherapy + targeted therapy + chemotherapy | Nivolumab + bevacizumab + paclitaxel | |
Melanoma | Tang et al[55] | Clinical study | Immunotherapy + targeted therapy + chemotherapy | Anti-PD-1 + axitinib +TACE |
Hong et al[56] | Case report | Immunotherapy + cryoablation | Anti-PD-1 + cryoablation | |
Blomen et al[57] | Clinical study | Dual imunotherapy + liver-specific therapies | Nivolumab + ipilimumab + liver-specific therapies | |
Gastric cancer | Xu et al[32] | Case report | Immunotherapy + radiotherapy | Anti-PD-L1 + radiotherapy |
Wang et al[58] | Case report | Immunotherapy + targeted therapy | Camrelizumab + lenvatinib | |
Peng et al[59] | Case report | Immunotherapy + chemotherapy | AK104 (a PD-1/CTLA-4 bispecific antibody) + mXELOX | |
Gastric hepatoid adenocarcinoma | Liu et al[60] | Case report | Immunotherapy + targeted therapy + chemotherapy | Pembrolizumab + bevacizumab + epirubicin + albumin binding paclitaxel |
Nasopharyngeal cancer | Zhang et al[61] | Case report | Immunotherapy + chemotherapy | Anti-PD-1 + TP regimen (nab-paclitaxel + cisplatin) |
Cervical cancer | Nance et al[62] | Case report | Immunotherapy + radiotherapy | Pembrolizumab + Yttrium-90 (Y90) |
The effectiveness of immunotherapy combined with chemotherapy has been demonstrated by multiple studies targeting various malignant tumors. A subgroup analysis of 115 NSCLC liver metastasis patients in the KEYNOTE-189 study found that the combination of pembrolizumab and chemotherapy significantly prolonged the median overall survival (OS) and PFS of patients compared to the chemotherapy combined with placebo group[24]. A meta-analysis that included eight randomized controlled clinical studies showed that PD-1/PD-L1 inhibitors + chemotherapy can reduce the risk of tumor progression (hazard ratio [HR] = 0.60, 95% confidence interval [CI]: 0.55-0.65) and mortality (HR = 0.71, 95%CI: 0.58-0.90)[25]. A study by Inoue et al[26] on liver metastasis in colorectal cancer found that the infiltration of CD8(+), CD3(+), and CD56(+) cells in the cetuximab + chemotherapy group was higher than that in the chemotherapy group and no chemotherapy group (P < 0.05 for all). The efficacy of combination immunotherapy regimen for liver metastasis of many malignant tumors is worth further investigation. Some phase III clinical studies[27,28] have shown that chemotherapy combined with immunotherapy can improve treatment efficacy and prognosis in advanced gastric cancer patients, but clinical studies on immunotherapy for liver metastasis of gastric cancer are extremely limited. Preclinical studies have also yielded some clinically instructive results. Ho et al[29] observed that gemcitabine + PD-1 antibody significantly prolonged the median survival time (66 d vs 56 d) of mice with liver metastasis of pancreatic cancer compared with gemcitabine alone. They also found that the combination therapy can enhance the anti-cancer effect and Th1 Lymphocytes response of M1 macrophages.
Studies have shown that liver targeted radiation therapy can reshape the liver immune microenvironment, reduce T cell consumption, and restore the effectiveness of immunotherapy[20]. Similar studies on NSCLC have shown that local liver radiation therapy can lead to a higher proportion of CD8(+) T cells and CD4(+) T cells in tumor tissue, and the surface of tumor cells will also express higher levels of PD-1/PD-L1. Therefore, radiotherapy combined with immunization may also be an effective treatment for NSCLC patients with liver metastases[30]. In recent years, the effectiveness of stereotactic body radiation therapy (SBRT) has been confirmed for lung cancer liver metastasis. The addition of SBRT in NSCLC liver metastasis patients can promote the anti-angiogenic effect, enhance the immunogenicity of tumors in chemotherapy and immunotherapy, and thus achieve a synergistic effect with systemic therapy[31]. Xu et al[32] reported a case of gastric cancer with liver metastasis, which progressed after chemotherapy and targeted therapy, but, after changing the treatment strategy to PD-1 antibody combined with SBRT, partial response was achieved.
In a mouse model of colon cancer liver metastasis, it was found that the anti-tumor effect of blocking PD-1 checkpoint alone was not significant, while immunotherapy combined with VEGF inhibitors significantly improved the therapeutic effect. This indicates that VEGF inhibitors may sensitize the antitumor effects of immunotherapy[33]. At present, the combination of angiogenesis inhibitors and anti-PD-1/PD-L1 has become the first-line treatment for patients with metastatic renal cell carcinoma. In the IMpower150 study[34] for metastatic NSCLC, it was found that for patients with liver metastasis, the atezolizumab + bevacizumab + carboplatin + paclitaxel group (ABCP group) had longer OS and PFS compared to the bevacizumab + carboplatin + paclitaxel group (BCP group). Immunotherapy combined with antivascular therapy is of great significance for patients with liver metastasis.
Considering the immune tolerance of the liver, the combination therapy of dual drug inhibition at immune checkpoints is expected to have a synergistic effect on liver metastasis patients and achieve better therapeutic effects. The CheckMate 277 study[35] evaluated the efficacy in the nivolumab combined with ipilimumab group and chemotherapy group of advanced or metastatic NSCLC patients. The results showed that the dual immunotherapy significantly improved patient efficacy compared to the chemotherapy group (2-year ORR: 40.0% vs 32.8%; median OS: 17.1 mo vs 13.9 mo, P = 0.007). Although there have been no reports of dual immunotherapy for melanoma liver metastases, CheckMate067 study[36] found that the combined treatment of nivolumab and ipilimumab compared with the monotherapy could improve the OS of melanoma patients, which also suggests that the potential value of dual immunotherapy is worth further exploration.
In clinical practice, in order to improve efficacy, there are often not only dual combination therapies, but also multiple combination therapy methods. For example, the Impower150 study used a combination of four treatment methods to sig
There are still many combination therapy methods that are still being explored in clinical research or continuously attempted in preclinical studies. Matsumoto et al[38] found that, the combination of an immune stimulator [alpha-galactosylceramide (KRN7000)] and an angiogenesis inhibitor [AGM-1470 (TNP470)] can significantly inhibit the growth of liver metastases from pancreatic cancer, produce synergistic effects, and improve the therapeutic effect; in a mouse model of colon cancer liver metastasis, the use of lipopolysaccharide trapping system can improve the efficacy of PD-L1 monoclonal antibody[39]. Hu et al[40] confirmed that up-regulating the expression of the relaxin (RLN) gene can further produce synergistic anti-metastasis effect with PD-L1 in the mouse models of liver metastasis of colorectal cancer, pancreatic cancer, and breast cancer. Although these treatment methods have not yet been translated into clinical applications, basic research is more conducive to developing more scientific combination therapy strategies from the mechanism level, which is conducive to further improving the treatment prognosis of liver metastasis patients through clinical translation.
The side effects of combination therapy in patients are also an important evaluation indicator for the selection of treat
Patients with malignant tumor liver metastasis have a poor prognosis. The liver, as an immune tolerant organ, presents a challenge in clinical treatment due to the decreased efficacy of immunotherapy after liver metastasis. It is of great significance to conduct in-depth research on the characteristics of the liver immune microenvironment and identify potential combination therapy targets for the development of new combination therapy strategies for liver metastasis patients. The combination of immunotherapy with chemotherapy, anti-vascular therapy, or radiotherapy, and dual immunotherapy may all improve the anti-tumor effect of monotherapy. However, current clinical research is still relatively limited, and the safety and effectiveness of combination therapy still need to be further evaluated. In the future, more clinical and translational studies should be carried out to optimize immunotherapy strategies through systematic evaluation schemes, so that liver metastasis patients can gain greater benefits from immunotherapy.
1. | Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer. 2021;21:541-557. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 88] [Cited by in F6Publishing: 222] [Article Influence: 74.0] [Reference Citation Analysis (0)] |
2. | Horn SR, Stoltzfus KC, Lehrer EJ, Dawson LA, Tchelebi L, Gusani NJ, Sharma NK, Chen H, Trifiletti DM, Zaorsky NG. Epidemiology of liver metastases. Cancer Epidemiol. 2020;67:101760. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 45] [Cited by in F6Publishing: 117] [Article Influence: 29.3] [Reference Citation Analysis (0)] |
3. | de Ridder J, de Wilt JH, Simmer F, Overbeek L, Lemmens V, Nagtegaal I. Incidence and origin of histologically confirmed liver metastases: an explorative case-study of 23,154 patients. Oncotarget. 2016;7:55368-55376. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 61] [Cited by in F6Publishing: 88] [Article Influence: 14.7] [Reference Citation Analysis (0)] |
4. | Oliveira RC, Alexandrino H, Cipriano MA, Alves FC, Tralhão JG. Predicting liver metastases growth patterns: Current status and future possibilities. Semin Cancer Biol. 2021;71:42-51. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis (0)] |
5. | Garcia-Vicién G, Mezheyeuski A, Bañuls M, Ruiz-Roig N, Molleví DG. The Tumor Microenvironment in Liver Metastases from Colorectal Carcinoma in the Context of the Histologic Growth Patterns. Int J Mol Sci. 2021;22. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis (0)] |
6. | Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14-27. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 175] [Cited by in F6Publishing: 440] [Article Influence: 88.0] [Reference Citation Analysis (0)] |
7. | Barnhill R, van Dam PJ, Vermeulen P, Champenois G, Nicolas A, Rawson RV, Wilmott JS, Thompson JF, Long GV, Cassoux N, Roman-Roman S, Busam KJ, Scolyer RA, Lazar AJ, Lugassy C. Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value. J Pathol Clin Res. 2020;6:195-206. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis (0)] |
8. | Latacz E, Höppener D, Bohlok A, Leduc S, Tabariès S, Fernández Moro C, Lugassy C, Nyström H, Bozóky B, Floris G, Geyer N, Brodt P, Llado L, Van Mileghem L, De Schepper M, Majeed AW, Lazaris A, Dirix P, Zhang Q, Petrillo SK, Vankerckhove S, Joye I, Meyer Y, Gregorieff A, Roig NR, Vidal-Vanaclocha F, Denis L, Oliveira RC, Metrakos P, Grünhagen DJ, Nagtegaal ID, Mollevi DG, Jarnagin WR, D'Angelica MI, Reynolds AR, Doukas M, Desmedt C, Dirix L, Donckier V, Siegel PM, Barnhill R, Gerling M, Verhoef C, Vermeulen PB. Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. Br J Cancer. 2022;127:988-1013. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis (0)] |
9. | Galjart B, Nierop PMH, van der Stok EP, van den Braak RRJC, Höppener DJ, Daelemans S, Dirix LY, Verhoef C, Vermeulen PB, Grünhagen DJ. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases. Angiogenesis. 2019;22:355-368. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 63] [Cited by in F6Publishing: 86] [Article Influence: 17.2] [Reference Citation Analysis (0)] |
10. | Buisman FE, van der Stok EP, Galjart B, Vermeulen PB, Balachandran VP, Coebergh van den Braak RRJ, Creasy JM, Höppener DJ, Jarnagin WR, Kingham TP, Nierop PMH, Sadot E, Shia J, Groot Koerkamp B, Grünhagen DJ, D'Angelica M, Verhoef C. Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases. Clin Exp Metastasis. 2020;37:593-605. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 14] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis (0)] |
11. | Pao W, Ooi CH, Birzele F, Ruefli-Brasse A, Cannarile MA, Reis B, Scharf SH, Schubert DA, Hatje K, Pelletier N, Spleiss O, Reed JC. Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer. Cancer Discov. 2018;8:395-402. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 45] [Cited by in F6Publishing: 61] [Article Influence: 10.2] [Reference Citation Analysis (0)] |
12. | Botticelli A, Cirillo A, Scagnoli S, Cerbelli B, Strigari L, Cortellini A, Pizzuti L, Vici P, De Galitiis F, Di Pietro FR, Cerbelli E, Ghidini M, D'Amati G, Della Rocca C, Mezi S, Gelibter A, Giusti R, Cortesi E, Ascierto PA, Nuti M, Marchetti P. The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. Vaccines (Basel). 2020;8. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis (0)] |
13. | Takeyasu Y, Yoshida T, Shibaki R, Matsumoto Y, Goto Y, Kanda S, Horinouchi H, Yamamoto N, Motoi N, Ohe Y. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC. Clin Lung Cancer. 2021;22:127-133.e3. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
14. | Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017;5:417-424. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 263] [Cited by in F6Publishing: 393] [Article Influence: 56.1] [Reference Citation Analysis (0)] |
15. | Wang X, Ji Q, Yan X, Lian B, Si L, Chi Z, Sheng X, Kong Y, Mao L, Bai X, Tang B, Li S, Zhou L, Cui C, Guo J. The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. Front Oncol. 2020;10:546604. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis (0)] |
16. | Liu K, Wu CX, Liang H, Wang T, Zhang JY, Wang XT. Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis. World J Gastrointest Surg. 2024;16:700-709. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
17. | Thomson AW, Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol. 2010;10:753-766. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 528] [Cited by in F6Publishing: 557] [Article Influence: 39.8] [Reference Citation Analysis (0)] |
18. | Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol. 2017;17:306-321. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 621] [Cited by in F6Publishing: 853] [Article Influence: 121.9] [Reference Citation Analysis (0)] |
19. | Kubes P, Jenne C. Immune Responses in the Liver. Annu Rev Immunol. 2018;36:247-277. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 296] [Cited by in F6Publishing: 467] [Article Influence: 77.8] [Reference Citation Analysis (0)] |
20. | Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, Chopra Z, El Naqa I, Zhou J, Bian Y, Jiang L, Tezel A, Skvarce J, Achar RK, Sitto M, Rosen BS, Su F, Narayanan SP, Cao X, Wei S, Szeliga W, Vatan L, Mayo C, Morgan MA, Schonewolf CA, Cuneo K, Kryczek I, Ma VT, Lao CD, Lawrence TS, Ramnath N, Wen F, Chinnaiyan AM, Cieslik M, Alva A, Zou W. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021;27:152-164. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 234] [Cited by in F6Publishing: 486] [Article Influence: 162.0] [Reference Citation Analysis (0)] |
21. | Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Immunol. 2020;5. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 164] [Cited by in F6Publishing: 158] [Article Influence: 39.5] [Reference Citation Analysis (0)] |
22. | He Y, Han Y, Fan AH, Li D, Wang B, Ji K, Wang X, Zhao X, Lu Y. Multi-perspective comparison of the immune microenvironment of primary colorectal cancer and liver metastases. J Transl Med. 2022;20:454. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
23. | Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5:28. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 854] [Cited by in F6Publishing: 1015] [Article Influence: 253.8] [Reference Citation Analysis (0)] |
24. | Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, Hui R, Hochmair MJ, Clingan P, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Garon EB, Novello S, Rubio-Viqueira B, Boyer M, Kurata T, Gray JE, Yang J, Bas T, Pietanza MC, Garassino MC. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020;38:1505-1517. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 367] [Cited by in F6Publishing: 410] [Article Influence: 102.5] [Reference Citation Analysis (0)] |
25. | Qin BD, Jiao XD, Liu J, Liu K, He X, Wu Y, Ling Y, Duan XP, Qin WX, Wang Z, Zang YS. The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer. Crit Rev Oncol Hematol. 2020;147:102893. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 18] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis (0)] |
26. | Inoue Y, Hazama S, Suzuki N, Tokumitsu Y, Kanekiyo S, Tomochika S, Tsunedomi R, Tokuhisa Y, Iida M, Sakamoto K, Takeda S, Ueno T, Yoshino S, Nagano H. Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer. Cancer Sci. 2017;108:455-460. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
27. | Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27-40. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1201] [Cited by in F6Publishing: 1368] [Article Influence: 456.0] [Reference Citation Analysis (0)] |
28. | Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234-247. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 36] [Cited by in F6Publishing: 60] [Article Influence: 30.0] [Reference Citation Analysis (0)] |
29. | Ho TTB, Nasti A, Seki A, Komura T, Inui H, Kozaka T, Kitamura Y, Shiba K, Yamashita T, Mizukoshi E, Kawaguchi K, Wada T, Honda M, Kaneko S, Sakai Y. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis. J Immunother Cancer. 2020;8. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 52] [Cited by in F6Publishing: 65] [Article Influence: 16.3] [Reference Citation Analysis (0)] |
30. | Su TS, Liang P, Liang J, Lu HZ, Jiang HY, Cheng T, Huang Y, Tang Y, Deng X. Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2017;98:639-646. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 10.0] [Reference Citation Analysis (0)] |
31. | Klement RJ, Guckenberger M, Alheid H, Allgäuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Gerum S, Habermehl D, Hildebrandt G, Lewitzki V, Ostheimer C, Papachristofilou A, Petersen C, Schneider T, Semrau R, Wachter S, Andratschke N. Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol. 2017;123:227-233. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 60] [Cited by in F6Publishing: 78] [Article Influence: 11.1] [Reference Citation Analysis (0)] |
32. | Xu J, Liu H, Ni G, Huang Y, Liang H, Ni Y, Huang Q, Yang Z. Clinical efficacy of PD-1 inhibitor combined with radiotherapy in a multi-drug resistant patient with liver metastasis from gastric cancer. Front Surg. 2023;10:1101294. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
33. | Ragusa S, Prat-Luri B, González-Loyola A, Nassiri S, Squadrito ML, Guichard A, Cavin S, Gjorevski N, Barras D, Marra G, Lutolf MP, Perentes J, Corse E, Bianchi R, Wetterwald L, Kim J, Oliver G, Delorenzi M, De Palma M, Petrova TV. Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice. J Clin Invest. 2020;130:1199-1216. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis (0)] |
34. | Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378:2288-2301. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2076] [Cited by in F6Publishing: 2508] [Article Influence: 418.0] [Reference Citation Analysis (0)] |
35. | Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381:2020-2031. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 1702] [Article Influence: 340.4] [Reference Citation Analysis (0)] |
36. | Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480-1492. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 775] [Cited by in F6Publishing: 963] [Article Influence: 160.5] [Reference Citation Analysis (0)] |
37. | Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Lee A, Coleman S, Deng Y, Kowanetz M, Shankar G, Lin W, Socinski MA; IMpower150 Study Group. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7:387-401. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 432] [Cited by in F6Publishing: 637] [Article Influence: 127.4] [Reference Citation Analysis (0)] |
38. | Matsumoto G, Nagai S, Muta M, Tsuruta K, Okamoto A, Toi M. Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer. Oncol Rep. 2003;10:1201-1206. [PubMed] [Cited in This Article: ] |
39. | Song W, Tiruthani K, Wang Y, Shen L, Hu M, Dorosheva O, Qiu K, Kinghorn KA, Liu R, Huang L. Trapping of Lipopolysaccharide to Promote Immunotherapy against Colorectal Cancer and Attenuate Liver Metastasis. Adv Mater. 2018;30:e1805007. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 130] [Cited by in F6Publishing: 110] [Article Influence: 18.3] [Reference Citation Analysis (0)] |
40. | Hu M, Wang Y, Xu L, An S, Tang Y, Zhou X, Li J, Liu R, Huang L. Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy. Nat Commun. 2019;10:2993. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 92] [Cited by in F6Publishing: 80] [Article Influence: 16.0] [Reference Citation Analysis (0)] |
41. | Zhou X, Yao Z, Bai H, Duan J, Wang Z, Wang X, Zhang X, Xu J, Fei K, Zhang Z, Tan F, Xue Q, Gao S, Gao Y, Wang J, He J. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021;22:1265-1274. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 24] [Cited by in F6Publishing: 103] [Article Influence: 34.3] [Reference Citation Analysis (0)] |
42. | Voglhuber T, Eitz KA, Oechsner M, Vogel MME, Combs SE. Analysis of using high-precision radiotherapy in the treatment of liver metastases regarding toxicity and survival. BMC Cancer. 2021;21:780. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
43. | Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21:1381-1389. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 158] [Cited by in F6Publishing: 159] [Article Influence: 11.4] [Reference Citation Analysis (0)] |
44. | An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB, Jiang YY. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol. 2010;66:813-821. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 59] [Cited by in F6Publishing: 65] [Article Influence: 4.6] [Reference Citation Analysis (0)] |
45. | Ma K, Guo Q, Li X. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study. BMC Pulm Med. 2023;23:175. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 3] [Reference Citation Analysis (0)] |
46. | Jiang Y, Qiao S, Li L, Zhu X. Combination of radiotherapy and Anlotinib enhances benefit from immunotherapy to liver metastasis and abscopal tumor from lung cancer. Int Immunopharmacol. 2024;128:111441. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
47. | Wang F, He MM, Yao YC, Zhao X, Wang ZQ, Jin Y, Luo HY, Li JB, Wang FH, Qiu MZ, Lv ZD, Wang DS, Li YH, Zhang DS, Xu RH. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. Cell Rep Med. 2021;2:100383. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 52] [Article Influence: 17.3] [Reference Citation Analysis (0)] |
48. | Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20:849-861. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 226] [Cited by in F6Publishing: 355] [Article Influence: 71.0] [Reference Citation Analysis (0)] |
49. | Kadota H, Yuge R, Shimizu D, Miyamoto R, Otani R, Hiyama Y, Takigawa H, Hayashi R, Urabe Y, Kitadai Y, Oka S, Tanaka S. Anti-Programmed Cell Death-1 Antibody and Dasatinib Combination Therapy Exhibits Efficacy in Metastatic Colorectal Cancer Mouse Models. Cancers (Basel). 2022;14. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
50. | Qiu X, Lu C, Sha H, Zhu Y, Kong W, Tong F, Wang Q, Meng F, Liu B, Du J. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial. Front Immunol. 2024;15:1210859. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
51. | Blair AB, Wang J, Davelaar J, Baker A, Li K, Niu N, Shao Y, Funes V, Li P, Pachter JA, Maneval DC, Dezem F, Plummer J, Chan KS, Gong J, Hendifar AE, Pandol SJ, Burkhart R, Zhang Y, Zheng L, Osipov A. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. Gastroenterology. 2022;163:1267-1280.e7. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis (0)] |
52. | Zhang B, Tang K, Dong X. A case of pancreatic cancer treated with chemotherapy combined with immunotherapy and targeted therapy. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023;52:578-582. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
53. | Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Investigators. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44-59. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 503] [Cited by in F6Publishing: 714] [Article Influence: 142.8] [Reference Citation Analysis (0)] |
54. | Ozaki Y, Tsurutani J, Mukohara T, Iwasa T, Takahashi M, Tanabe Y, Kawabata H, Masuda N, Futamura M, Minami H, Matsumoto K, Yoshimura K, Kitano S, Takano T. Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer. Data Brief. 2022;45:108558. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 1] [Reference Citation Analysis (0)] |
55. | Tang B, Mo J, Yan X, Duan R, Chi Z, Cui C, Si L, Kong Y, Mao L, Li S, Zhou L, Lian B, Wang X, Bai X, Xu H, Li C, Dai J, Guo J, Sheng X. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma. Eur J Cancer. 2021;156:83-92. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis (0)] |
56. | Hong H, Shen L, Tan H, Wu Y, Liu Y, Fan W. Local treatment of liver metastasis in a patient with advanced malignant melanoma: A case report. J Cancer Res Ther. 2023;19:1675-1679. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
57. | Blomen CL, Kött J, Hartung TI, Torster LK, Gebhardt C. Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance? Cancers (Basel). 2021;13. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
58. | Wang K, Wang H, Lv Y, Liu H, Liu J, Zhang Y. Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report. Ann Palliat Med. 2021;10:803-809. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
59. | Peng J, Zhu Q, Peng Z, Chen Z, Liu Y, Liu B. Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report. Front Immunol. 2022;13:1049518. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
60. | Liu M, Luo C, Xie ZZ, Li X. Treatment of gastric hepatoid adenocarcinoma with pembrolizumab and bevacizumab combination chemotherapy: A case report. World J Clin Cases. 2022;10:5420-5427. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis (2)] |
61. | Zhang J, Tang H, Li H, Jiang D, Luo H. Case report of chemoradiotherapy combined with immunotherapy for liver metastasis and lymph node metastases in the head of the pancreas of nasopharyngeal carcinoma. Arch Med Sci. 2022;18:1413-1419. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Reference Citation Analysis (0)] |
62. | Nance ME, Biedermann GB, Bhat AP, Davis RM. Chemorefractory liver metastasis from cervical cancer successfully treated with a combination of yttrium-90 and immunotherapy. Radiol Case Rep. 2020;15:1359-1365. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis (0)] |